Personalized, adaptive deep brain stimulation (DBS) can enhance the control of motor symptoms of Parkinson's disease (PD) compared with standard DBS, new research suggests. In a blinded randomized ...
On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...
DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first ...
At 40, Keith Krehbiel was a successful political scientist with a distinguished professorship, an award-winning book and a membership at the American Academy of Arts and Sciences. But he also was ...
More than 10 million people globally live with Parkinson’s disease, for which there is currently no cure. Deep brain stimulation (DBS) is a surgical treatment that helps alleviate some movement ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adaptive ...
Newronika Closes €13.6 Million Series B Financing to Accelerate Development of Adaptive DBS Platform
MILAN, Feb. 13, 2025 /PRNewswire/ -- Newronika, a global leader in advanced deep brain stimulation, is pleased to announce the successful closing of its €13.6 million Series B funding round. The ...
Medtronic plc’s Brainsense adaptive deep brain stimulation system has been shown to be tolerable, effective and safe for long-term use at home in people with Parkinson’s disease. A study published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback